# Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy

> **NCT01874431** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 823 (actual)

## Conditions studied

- Diabetic Nephropathies

## Interventions

- **DRUG:** Finerenone (BAY94-8862)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01874431
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-12
- **Primary completion:** 2014-07-09
- **Final completion:** 2014-08-07
- **Target enrollment:** 823 (ACTUAL)
- **Last updated:** 2021-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01874431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01874431, "Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01874431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*